Search alternatives:
point decrease » point increase (Expand Search)
non decrease » note decreased (Expand Search), fold decrease (Expand Search), mean decrease (Expand Search)
nn decrease » _ decrease (Expand Search), mean decrease (Expand Search), gy decreased (Expand Search)
a decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
e point » _ point (Expand Search), 5 point (Expand Search), a point (Expand Search)
5 non » _ non (Expand Search), a non (Expand Search), e non (Expand Search)
point decrease » point increase (Expand Search)
non decrease » note decreased (Expand Search), fold decrease (Expand Search), mean decrease (Expand Search)
nn decrease » _ decrease (Expand Search), mean decrease (Expand Search), gy decreased (Expand Search)
a decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
e point » _ point (Expand Search), 5 point (Expand Search), a point (Expand Search)
5 non » _ non (Expand Search), a non (Expand Search), e non (Expand Search)
-
201
Effects of FE and RUD wrist postures on carpal tunnel volume distribution by quartile.
Published 2022Subjects: -
202
-
203
Delphinidin alters VEGF-A splicing to increase VEGF-A<sub>165</sub>b and decrease total VEGF-A expression.
Published 2019“…<p><b>A)</b> Treatment of podocytes with delphinidin chloride (10 μg/ml) under normal glucose (NG; 5 mM glucose + 25 mM mannitol) and high glucose (HG; 30 mM glucose, 1 ng/ml TNFα, 1 ng/ml IL-6, and 100 nM insulin) for 48 hrs increased the protein expression of VEGF-A<sub>165</sub>b relative to total VEGF-A<sub>165</sub> (quantified in <b>B</b>; *p<0.05 vs NG, †p<0.05 vs HG; n = 3 biological repeats; One-way ANOVA with Bonferroni post-hoc test for comparison between pairs; <b>A</b>—the same blot was first probed with VEGF-A<sub>165</sub>b before stripping and reprobing with panVEGF-A). …”
-
204
-
205
-
206
Table 1_Previous treatment decreases efficacy of pralsetinib in RET fusion-positive non-small-cell lung cancer.doc
Published 2025“…Background<p>Pralsetinib is a selective RET inhibitor. The ARROW trial revealed that RET fusion-positive non-small-cell lung cancer (NSCLC) can benefit from pralsetinib with tolerable adverse events (AEs). …”
-
207
-
208
-
209
-
210
-
211
-
212
-
213
-
214
Decreased MBP levels in the brain in <i>Large</i><sup><i>myd/myd</i></sup> mice.
Published 2020“…<b>B,</b> Whole-brain lysates of P7 control and <i>Large</i><sup><i>myd/myd</i></sup> mice (<i>n</i> = 5) were obtained for MBP immunoblotting. Decreased expression levels of MBP were observed in <i>Large</i><sup><i>myd/myd</i></sup> mice compared with those in control mice. …”
-
215
-
216
-
217
-
218
-
219
-
220